Results 241 to 250 of about 3,754,903 (381)
This study develops a human engineered heart tissue‐derived model of diabetic cardiomyopathy that accurately replicates the dynamic changes in the structural, contractile, and electrophysiological properties of the myocardium. Furthermore, this model is used to confirm the direct protective effects of empagliflozin on the heart through an SGLT2 off ...
Lin Cai+9 more
wiley +1 more source
Persistent Monocytic Bioenergetic Impairment and Mitochondrial DNA Damage in PASC Patients with Cardiovascular Complications. [PDF]
Semo D+8 more
europepmc +1 more source
CCS‐RSF@PRP hydrogel is engineered to structurally and functionally mimic the blood clot by integrating PPR, CCS, and RSF nanofibers through in situ activation of PRP. In a rat periodontitis model, CCS‐RSF@PRP hydrogel effectively promotes periodontal tissue repair, attributing to neutralizing the multiple proinflammatory mediators, thus rebuilding a ...
Yini Huangfu+14 more
wiley +1 more source
Novel biomarker panel combined with imaging parameters for predicting cardiovascular complications in diabetic patients: a retrospective cohort study. [PDF]
Guo J, Zhang Z.
europepmc +1 more source
By catalyzing FAM134B ubiquitination and activating ER‐phagy, AMFR alleviates progressive fibrosis and cardiac dysfunction by inhibiting the mTORC1 pathway. Consequently, these findings underscore the essential role of AMFR‐driven ER‐phagy in mitigating the progression of fibrotic responses, offering a potential therapeutic target for preventing heart ...
Zhixiang Wang+10 more
wiley +1 more source
This study introduces a strategy for engineering heterogeneous surface and bulk structures within a single material, termed phase‐separation and underwater reconfiguration‐enhanced (PURE) elastomers. These elastomers combine high bulk elasticity with enhanced immunocompatibility at the surface.
Xianchi Zhou+10 more
wiley +1 more source
Critical cardiovascular complications during non-immunosuppressive therapy for VEXAS syndrome. [PDF]
Saito Y, Suzuki S, Ikeda K, Morimoto S.
europepmc +1 more source